Enzo Biochem (NYSE:ENZ) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Enzo Biochem, Inc. (NYSE:ENZ) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.11 and traded as high as $1.14. Enzo Biochem shares last traded at $1.13, with a volume of 21,865 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Enzo Biochem in a research report on Wednesday. They set a “hold” rating on the stock.

Enzo Biochem Price Performance

The stock has a 50-day moving average price of $1.13 and a two-hundred day moving average price of $1.11.

Institutional Trading of Enzo Biochem

A hedge fund recently raised its stake in Enzo Biochem stock. Renaissance Technologies LLC increased its position in Enzo Biochem, Inc. (NYSE:ENZ) by 2.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,499,546 shares of the medical research company’s stock after acquiring an additional 64,417 shares during the period. Renaissance Technologies LLC owned approximately 4.86% of Enzo Biochem worth $2,725,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 36.90% of the stock is currently owned by hedge funds and other institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.